Drug Approval | February 19, 2022
US FDA to review Amylyx new drug application for AMX0035
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Virginia will be responsible for meeting client needs for both media and commercial analytics.
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Funding to grow the insurance and digital therapeutics vertical in India
Parkinson's disease treatment is the first and only carbidopa/levodopa (CD/LD) tablet designed to be divided for precise dosing
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
The first patient in India treated at Jaslok Hospital and Research Centre, Mumbai Includes the world’s smallest implantable spinal cord stimulator
The Ayurveda storefront will enhance visibility of unique Ayurveda products from Indian small businesses and D2C brands
Subscribe To Our Newsletter & Stay Updated
